Development of technolgy for the large-scale production of a novel dendritic cell vaccine for the treatment of glioblastoma

We plan to isolate and expand glioblastoma (GBM) cells from commercially available fresh tumor tissue. These cells will be used to create tumor antigen libraries that, in a clinical setting, would be able to prime GBM patients' dendritic cells to present Tumor Associated Antigens (TAAs) to immune cells for a targeted therapy. The cell lines created during this project will only be used for research purposes, as a proof of concept that the technology can be adapted to production at large scale.